R R

What Is Qelbree?

Qelbree is a prescription medication containing viloxazine in an extended-release capsule. It is classified as a selective norepinephrine reuptake inhibitor and is approved to treat attention-deficit/hyperactivity disorder (ADHD) in adults and children aged six years and older. Qelbree is a nonstimulant medication and is not classified as a controlled substance in the United States. It helps manage ADHD symptoms, including difficulties with attention, impulsivity, and hyperactivity. Qelbree is taken once daily, and its use requires monitoring for mood changes, blood pressure effects, and medication interactions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Qelbree?

Qelbree is a prescription medication containing viloxazine in an extended-release capsule. It is classified as a selective norepinephrine reuptake inhibitor and is approved to treat attention-deficit/hyperactivity disorder (ADHD) in adults and children aged six years and older. Qelbree is a nonstimulant medication and is not classified as a controlled substance in the United States. It helps manage ADHD symptoms, including difficulties with attention, impulsivity, and hyperactivity. Qelbree is taken once daily, and its use requires monitoring for mood changes, blood pressure effects, and medication interactions.

read more about qelbree ...

Copy this HTML:

Copy HTML Copied!

How Does Qelbree Work?

Qelbree inhibits the reuptake of norepinephrine, a neurotransmitter involved in attention and other nervous system functions. This increases norepinephrine availability in the brain, although the precise mechanism responsible for its effects on ADHD symptoms is not fully established. Viloxazine also affects certain serotonin-related pathways. Unlike traditional stimulant ADHD medications, Qelbree is not an amphetamine or methylphenidate product. It can influence the metabolism of other medications by inhibiting CYP1A2, an important liver enzyme. These interactions require review before treatment begins.

What Condition Does Qelbree Treat?

Qelbree is approved for ADHD in adults and pediatric patients aged six years and older. ADHD can involve persistent difficulties with attention, organization, impulsivity, and activity regulation that interfere with daily functioning. Qelbree provides a nonstimulant treatment option for patients whose clinical needs support its use. A healthcare professional assesses symptoms, medical history, other medications, and coexisting mental health conditions before prescribing it. Patients should be screened for bipolar disorder because treatment can trigger mania or hypomania. Qelbree is not approved for children younger than six years.

How Should Qelbree Be Taken?

Qelbree is taken orally once daily, with or without food. Children aged six through 11 years generally begin at 100 mg daily, with weekly increases up to 400 mg daily when needed. Adolescents aged 12 through 17 years usually begin at 200 mg daily, with a maximum of 400 mg daily. Adults generally begin at 200 mg daily and may increase to a maximum of 600 mg daily. Capsules can be swallowed whole or opened and sprinkled onto applesauce or pudding according to the label. Patients with severe kidney impairment require lower doses. Capsules or their contents should not be chewed.

What Are the Side Effects and Warnings of Qelbree?

Common adverse effects include sleepiness, fatigue, reduced appetite, nausea, insomnia, headache, and irritability. Qelbree carries a boxed warning for increased suicidal thoughts and behaviors, requiring monitoring for new or worsening mood changes. It can also increase blood pressure and heart rate and may trigger mania or hypomania in susceptible patients. Qelbree must not be taken with monoamine oxidase inhibitors or certain medications metabolized through CYP1A2. Patients should report suicidal thoughts, significant behavioral changes, palpitations, or severe sleepiness. Blood pressure and heart rate should be checked before treatment, after dose increases, and periodically afterward.

Common Questions About Qelbree

Is Qelbree a stimulant medication?

No. Qelbree is a nonstimulant medication containing viloxazine extended-release. It is not classified as a controlled substance.

Can adults take Qelbree for ADHD?

Yes. Qelbree is approved for ADHD in adults and children aged six years and older.

How often is Qelbree taken?

Qelbree is taken once daily. Starting doses and maximum doses differ between children, adolescents, and adults.

Can Qelbree cause mood changes?

Yes. Qelbree carries a boxed warning for suicidal thoughts and behaviors. Patients and caregivers should report new depression, unusual behavior, or suicidal thoughts promptly.

References

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. https://pubmed.ncbi.nlm.nih.gov/35896943/. Date Accessed November 2, 2026.

An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. https://pubmed.ncbi.nlm.nih.gov/39373844/. Date Accessed November 2, 2026.

DailyMed - QELBREE (viloxazine hydrochloride) extended-release capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a. Date Accessed November 2, 2026.

Viloxazine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621027.html. Date Accessed November 2, 2026.

Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial. The Journal of Clinical Psychiatry. https://pubmed.ncbi.nlm.nih.gov/42207988/. Date Accessed November 2, 2026.